Yearly zoledronic acid in postmenopausal osteoporosis
Chang, J.T.
New England Journal of Medicine 357(7): 713
2007
ISSN/ISBN: 0028-4793 PMID: 17703528 Document Number: 606076
Document emailed within 1 workday
Related Documents
Karam, R.; Camm, J.; McClung, M. 2007: Yearly zoledronic acid in postmenopausal osteoporosis New England Journal of Medicine 357(7): 712Cohen, P.R. 2015: Zoledronic acid-associated symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): report of baboon syndrome in a woman with recurrent metastatic breast cancer after receiving zoledronic acid Dermatology Online Journal 21(8)
Rahnama, M.; Swiatkowski, W.; Zareba, S.ła. 2002: Assessment of the alkaline (ALP) and acid phosphatase (ACP) in the blood serum of rats during experimental postmenopausal osteoporosis Roczniki Panstwowego Zakladu Higieny 53(3): 283-291
Krylov, M.I.; Korotkova, T.A.; Miakotkin, V.A.; Benevolenskaia, L.I. 2004: Allele polymorphism of alkaline phosphatase, acid soluble phosphatase, and vitamin D-binding protein genes in postmenopausal osteoporosis Terapevticheskii Arkhiv 76(5): 61-65
Wynn, R.L. 2011: Zoledronic acid and osteonecrosis of the jaw: incidence varies with use General Dentistry 59(5): 330-332
De Luca, A.; Normanno, N. 2009: Endocrine therapy plus zoledronic acid in premenopausal breast cancer New England Journal of Medicine 360(22): 2368-2369; Author Reply 2369-2370
Larivière, M.; Beauvais, B.; Aziz, M.; Garin, J.F.; Abeloos, J.; Derouin, F.; Bamba, M.; Ferly-Therizol, M.; Sarfati, C.; Basset, D. 1989: A study in the Ivory Coast (1985-1987) of the efficacy and tolerance of ivermectin (Mectizan) in human onchocerciasis. II. Evaluation in the light of mass campaigns on the effect of yearly or half-yearly administration of single oral doses of 100, 150 or 200 mcg/kg Bulletin de la Societe de Pathologie Exotique et de Ses Filiales 82(1): 48-57
Jenícek, J.; Zivný, J. 1998: Postmenopausal osteoporosis Ceska Gynekologie 63(3): 240-244
Yodfat, Y. 2007: What's new in postmenopausal osteoporosis Harefuah 146(2): 134-9 164
Jesserer, H. 1988: What is appropriate in postmenopausal osteoporosis? Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 43(15): 416-418
Miki, T.; Tamura, A. 2006: Postmenopausal osteoporosis Nihon Rinsho. Japanese Journal of Clinical Medicine Suppl 2: 81-86
Vaughan, C.C. 1976: Rehabilitation in postmenopausal osteoporosis Israel Journal of Medical Sciences 12(7): 652-659
Chestnut, C. 1996: Postmenopausal osteoporosis: an overview American Journal of Therapeutics 3(10): 715-719
Chapurlat, R.; Delmas, P.D. 2004: Treatment of postmenopausal osteoporosis La Revue du Praticien 54(19): 2120-2126
Reginster, J.Y.; Devogelaer, J.P.; Kaufman, J.M.; Appelboom, T.; Vanhaelst, L. 1999: Postmenopausal osteoporosis in women Revue Medicale de Liege 54(4): 335-340
Ribot, C.; Trémollières, F.; Pouillès, J.-M. 2005: Management of postmenopausal osteoporosis La Revue du Praticien 55(4): 393-400
Liu, A.C. 1998: Treatment of postmenopausal osteoporosis New England Journal of Medicine 339(3): 202; Author Reply 203
Rodionova, S.S. 1997: The postmenopausal form of osteoporosis Terapevticheskii Arkhiv 69(10): 21-24
Okagawa, Y.; Sato, Y.; Onuma, H.; Osuga, T.; Hayashi, T.; Sato, T.; Miyanishi, K.; Kobune, M.; Takimoto, R.; Kato, J. 2015: A Case of Fanconi Syndrome Induced by Zoledronic Acid in a Metastatic Colorectal Cancer Patient Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(7): 867-870
Meng, Y.-h.; Peng, Y.; Liu, D.; Chen, Y.; Wang, H.; Liang, X. 2011: Study on the effects of zoledronic-acid-loaded collagen membrane on bone metabolism cells Zhonghua Kou Qiang Yi Xue Za Zhi 46(2): 107-111